نتایج جستجو برای: ret proto

تعداد نتایج: 37432  

Journal: :European journal of endocrinology 2001
F Basolo E Molinaro L Agate A Pinchera L Pollina G Chiappetta C Monaco M Santoro A Fusco P Miccoli R Elisei M Capezzone F Pacini

BACKGROUND RET proto-oncogene rearrangements (RET/PTC) are causative events in the pathogenesis of a subset of papillary thyroid cancer (PTC). The prevalence of RET/PTC varies in different countries and according to specific clinical features: it is higher after radiation exposure and it is claimed to be higher in young patients. Conflicting results are reported regarding the prognostic role of...

Journal: :Cancer research 2005
Hirozumi Sawai Yuji Okada Kevork Kazanjian Joseph Kim Sascha Hasan Oscar J Hines Howard A Reber Dave S B Hoon Guido Eibl

Mutations of the RET proto-oncogene are responsible for several inherited human diseases and may function as genetic modifiers of the disease. However, the role of RET mutations in pancreatic cancer has not been studied. Expression of the glial cell line-derived neurotrophic factor (GDNF) receptors RET and GDNF family receptor alpha1 (GFRalpha1) in human pancreatic cancer cells was determined b...

2018
Zeanap A. Mabruk Samrein B.M. Ahmed Asha Caroline Thomas Sally A. Prigent

Preliminary screening data showed that the ShcD adaptor protein associates with the proto-oncogene RET receptor tyrosine kinase. In the present study, we aimed to investigate the molecular interaction between ShcD and RET in human neuroblastoma cells and study the functional impact of this interaction. We were able to show that ShcD immunoprecipitated with RET from SK-N-AS neuroblastoma cell ly...

Journal: :Cancer research 1997
S Ito T Iwashita N Asai H Murakami Y Iwata G Sobue M Takahashi

We investigated the transforming activity of the ret proto-oncogene with a mutation in cysteine 609, 611, 618, 620, 630, or 634 detected in patients with multiple endocrine neoplasia type 2A (MEN 2A), familial medullary thyroid carcinoma (FMTC), or Hirschsprung's disease. Of these cysteine mutations, codon 634 mutations are known to be correlated with the development of MEN 2A, whereas codon 60...

2006
Ivan Plaza-Menacho Roelof Koster Almer M. van der Sloot Wim J. Quax Jan Osinga Tineke van der Sluis Harry Hollema Grzegorz M. Burzynski Oliver Gimm Charles H.C.M. Buys Bart J.L. Eggen

The RET proto-oncogene encodes a receptor tyrosine kinase whose dysfunction plays a crucial role in the development of several neural crest disorders. Distinct activating RET mutations cause Multiple Endocrine Neoplasia type 2A (MEN2A), type 2B (MEN2B) and Familial Medullary Thyroid Carcinoma (FMTC). Despite clear correlations between the mutations found in these cancer syndromes and their phen...

Journal: :Human molecular genetics 1998
R A Decker M L Peacock P Watson

The RET proto-oncogene encodes a transmembrane receptor with tyrosine kinase activity. Germline mutations in RET are responsible for a number of inherited diseases. These include the dominantly inherited cancer syndromes multiple endocrine neoplasia types 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC), as well as some cases of familial Hirschsprung disease (HSCR1)...

2001
Anil V. Parwani William H. Westra Joel H. Blumin

A N ASYMPTOMATIC 9-year-old girl with normal childhood development was referred for DNA sequence analysis of the RET proto-oncogene on chromosome 10. She was the daughter of a woman with multiple endocrine neoplasia syndrome type 2A (MEN-2A). Genetic testing revealed a mutation involving codon 618 of the RET proto-oncogene that changed the wild-type TGC codon to a TCC codon. Her mother and 6-ye...

Journal: :Journal of clinical research in pediatric endocrinology 2016
Berna İmge Aydoğan Bağdagül Yüksel Mazhar Müslüm Tuna Mehtap Navdar Başaran Ayşen Akkurt Kocaeli Melek Eda Ertörer Kadriye Aydın Sibel Güldiken Yasin Şimşek Züleyha Cihan Karaca Merve Yılmaz Müjde Aktürk İnan Anaforoğlu Nur Kebapçı Cevdet Duran Abdullah Taşlıpınar Mustafa Kulaksızoğlu Alptekin Gürsoy Selçuk Dağdelen Murat Faik Erdoğan

OBJECTIVE This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic thyroidectomy (PTx) in mutation carriers were also assessed. METHODS G...

Journal: :Endocrine-related cancer 2007
Viktor Johanson Håkan Ahlman Peter Bernhardt Svante Jansson Lars Kölby Fredrik Persson Göran Stenman Christina Swärd Bo Wängberg Mats Stridsberg Ola Nilsson

Hereditary medullary thyroid carcinoma (MTC) is caused by germline mutations in the RET proto-oncogene, resulting in constitutive activation of the RET tyrosine kinase. A substantial proportion of sporadic MTCs also have RET mutations, making the RET tyrosine kinase a potential therapeutic target in MTC. We have established a transplantable MTC in nude mice from a sporadic human MTC carrying a ...

2006
Glenn M. Marshall Anne E. Peaston Stewart A. Smith Loen M. Hansford

Point mutations, deletions, and recombinations of the RET proto-onco gene are associated with several inherited human diseases of neural crest-derived cells: Hirschsprung's disease, familial medullary thyroid carcinoma, and the multiple endocrine neoplasia (MEN) syndromes, types 2A and 2B. RET expression is restricted to normal and malignant cells of neural crest origin, such as human neuroblas...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید